243 related articles for article (PubMed ID: 24059235)
1. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
[TBL] [Abstract][Full Text] [Related]
6. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Caponigro F
Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl transferase inhibitors in the treatment of breast cancer.
Kelland LR
Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
[TBL] [Abstract][Full Text] [Related]
9. Lonafarnib: First Approval.
Dhillon S
Drugs; 2021 Feb; 81(2):283-289. PubMed ID: 33590450
[TBL] [Abstract][Full Text] [Related]
10. Lonafarnib for cancer and progeria.
Wong NS; Morse MA
Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Dempke WC
Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Gordon LB; Kleinman ME; Miller DT; Neuberg DS; Giobbie-Hurder A; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland R; Snyder BD; Fligor B; Bishop WR; Statkevich P; Regen A; Sonis A; Riley S; Ploski C; Correia A; Quinn N; Ullrich NJ; Nazarian A; Liang MG; Huh SY; Schwartzman A; Kieran MW
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16666-71. PubMed ID: 23012407
[TBL] [Abstract][Full Text] [Related]
14. An overview on natural farnesyltransferase inhibitors for efficient cancer therapy.
Dai X; Sun Y; Zhang T; Ming Y; Hongwei G
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1027-1044. PubMed ID: 32308053
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
16. Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.
Porcu G; Parsons AB; Di Giandomenico D; Lucisano G; Mosca MG; Boone C; Ragnini-Wilson A
Mol Cancer; 2013 Aug; 12(1):88. PubMed ID: 23915247
[TBL] [Abstract][Full Text] [Related]
17. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibitors.
Hahn SM; Bernhard E; McKenna WG
Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
[TBL] [Abstract][Full Text] [Related]
20. Lonafarnib in cancer therapy.
Morgillo F; Lee HY
Expert Opin Investig Drugs; 2006 Jun; 15(6):709-19. PubMed ID: 16732721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
